DyslipidemiaPhase 1NCT02073084
A Thorough Corrected QT Interval Trial
A Phase 1 study testing K-877 Low Dose, Moxifloxacin and K-877 High Dose in people with Dyslipidemia, run by Kowa Research Institute, Inc. at 1 site in United States.
Trial summary
The purpose of this study is to determine the effects of K-877 on ECG parameters with a focus on cardiac repolarization compared with placebo in healthy adult subjects. Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Dyslipidemia
- What is being tested?
- K-877 Low Dose, Moxifloxacin and K-877 High Dose
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 56 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 2014to Mar 2014
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Subject provides written informed consent before any study specific evaluation is performed.
- Subject is a healthy adult male or female volunteer, of any race and ethnicity, between the ages of 18 and 45 years, inclusive.
- Subject has a body mass index of 18 to 30 kg/m2, inclusive.
Who cannot join
- Subject has clinically relevant abnormalities in the screening or check in assessments.
- Subject has a supine blood pressure after resting for at least 5 minutes that is higher than 140 mm Hg systolic or 90 mm Hg diastolic, or lower than 90 mm Hg systolic or 60 mm Hg diastolic.
- Subject has a supine Heart Rate (HR) (as measured at Screening or Check-in during collection of vital signs) after resting for at least 5 minutes that is outside the range of 40 to 90 beats per minute.
Trial locations and contacts
1 site in 1 country.
About this study
The purpose of this study is to determine the effects of K-877 on ECG parameters with a focus on cardiac repolarization compared with placebo in healthy adult subjects.
- Conditions
- Dyslipidemia
- Being tested
- K-877 Low Dose, Moxifloxacin, Placebo, K-877 High Dose
- Medical subject headings
- Dyslipidemias
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
K-877 Low DoseDrug
K-877 Low Dose
MoxifloxacinDrug
PlaceboOther
K-877 High DoseDrug
K-877 High Dose
| Study group | Role | What they receive |
|---|---|---|
| Sequence A | Other | Sequence A Receives: Drug: K-877 Low Dose; Drug: Moxifloxacin; Other: Placebo; Drug: K-877 High Dose |
| Sequence B | Other | Sequence B Receives: Drug: K-877 Low Dose; Drug: Moxifloxacin; Other: Placebo; Drug: K-877 High Dose |
| Sequence C | Other | Sequence C Receives: Drug: K-877 Low Dose; Drug: Moxifloxacin; Other: Placebo; Drug: K-877 High Dose |
| Sequence D | Other | Sequence D Receives: Drug: K-877 Low Dose; Drug: Moxifloxacin; Other: Placebo; Drug: K-877 High Dose |
What is being measured
The primary outcome is the main question the study is designed to answer.
QTcI (QT interval corrected) duration
Measured: 24 hrs
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2014 (estimated)
- Study startJan 2014
- Primary completionMar 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DyslipidemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 56 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kowa Research Institute, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02073084
- Sponsor's protocol ID
- K-877-102
- Status last verified
- Apr 2015
- First submitted
- 25 Feb 2014
- Last updated
- 10 Apr 2015
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Apr 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Thorough Corrected QT Interval Trial
- ClinicalTrials.gov ID
- NCT02073084
- Acronym / sponsor ID
- K-877-102
- Conditions
- Dyslipidemia
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 56 participants (actual)
- Lead sponsor
- Kowa Research Institute, Inc.Industry (pharma, biotech, devices)
- Study start
- Jan 2014
- Primary completion
- Mar 2014 (actual)
- First posted
- 27 Feb 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine the effects of K-877 on ECG parameters with a focus on cardiac repolarization compared with placebo in healthy adult subjects.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Sequence A | Other | Drug: K-877 Low Dose, Drug: Moxifloxacin, Other: Placebo, Drug: K-877 High DoseSequence A |
| Sequence B | Other | Drug: K-877 Low Dose, Drug: Moxifloxacin, Other: Placebo, Drug: K-877 High DoseSequence B |
| Sequence C | Other | Drug: K-877 Low Dose, Drug: Moxifloxacin, Other: Placebo, Drug: K-877 High DoseSequence C |
| Sequence D | Other | Drug: K-877 Low Dose, Drug: Moxifloxacin, Other: Placebo, Drug: K-877 High DoseSequence D |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Subject provides written informed consent before any study specific evaluation is performed.
- Subject is a healthy adult male or female volunteer, of any race and ethnicity, between the ages of 18 and 45 years, inclusive.
- Subject has a body mass index of 18 to 30 kg/m2, inclusive.
Key exclusion criteria (3 listed)
- Subject has clinically relevant abnormalities in the screening or check in assessments.
- Subject has a supine blood pressure after resting for at least 5 minutes that is higher than 140 mm Hg systolic or 90 mm Hg diastolic, or lower than 90 mm Hg systolic or 60 mm Hg diastolic.
- Subject has a supine Heart Rate (HR) (as measured at Screening or Check-in during collection of vital signs) after resting for at least 5 minutes that is outside the range of 40 to 90 beats per minute.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| K-877 Low DoseK-877 Low Dose | Drug | Sequence A, Sequence B, Sequence C, Sequence D |
| Moxifloxacin | Drug | Sequence A, Sequence B, Sequence C, Sequence D |
| Placebo | Other | Sequence A, Sequence B, Sequence C, Sequence D |
| K-877 High DoseK-877 High Dose | Drug | Sequence A, Sequence B, Sequence C, Sequence D |
Primary outcome
QTcI (QT interval corrected) duration
Time frame: 24 hrs
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Apr 2015.
Related trials for Dyslipidemia
Not yet recruiting
Plasma Lipids-Dependent Vitamin E Metabolism During Dynamic Hyperlipidemia
Lipid Metabolism Disorders
Active, not recruitingPhase 2
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
Diabetes, Lipodystrophy
RecruitingObservational study
A Study to Evaluate the Effectiveness and Safety of Fixed-Dose Combination of Pitavastatin/ Ezetimibe
Hypercholesterolemia, Dyslipidemias
Active, not recruitingPhase 3
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
Lipodystrophy, Diabetes
RecruitingObservational study
Causes and Natural History of Dyslipidemias
Hypercholesterolemia, Atherosclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing K-877 Low Dose, Moxifloxacin and K-877 High Dose in people with Dyslipidemia, run by Kowa Research Institute, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Apr 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
QTcI (QT interval corrected) duration (time frame: 24 hrs). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Apr 2015.